COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Stock Information for ProMIS Neurosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProMIS Neurosciences Inc.

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
Aeterna Zentaris and Ceapro Complete Merger Transaction
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.